Somatostatin Receptor Imaging in Cardiac Sarcoidosis

Cardiac Sarcoidosis Clinical Trial

Official title:

Somatostatin Receptor Imaging in Cardiac Sarcoidosis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02812849
• Other study ID #: 0001
• Status: Withdrawn
• Start date: June 2016
• Est. completion date: February 27, 2020

Study information

• Verified date: October 2020
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the trial is to determine the accuracy of Cu-64 labelled DOTATATE for diagnosing cardiac sarcoidosis using PET/CT or PET/MRI.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 27, 2020
• Est. primary completion date: November 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Group A: Suspected cardiac sarcoidosis Group B: Known cardiac sarcoidosis, clinical follow-up Group C: Myocarditis or dilated cardiomyopathy (Non-cardiac sarcoidosis)

Exclusion Criteria:

Infection Pregnancy Severe claustrophobia Weight >140 kg

Related Conditions & MeSH terms

• Cardiac Sarcoidosis
• Sarcoidosis

Intervention

Drug:
• Cu-64 DOTATATE

Locations

Country	Name	City	State
Denmark	Rigshospitalet	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity to detect cardiac sarcoidosis		1 day at PET/CT examination
Primary	Specificity to detect cardiac sarcoidosis		1 day at PET/CT examination